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Background: Neuroendocrine tumors (NETs) of the esophagus are extremely rare, and few cases have been reported
worldwide. Thus, a comprehensive nationwide study is needed to understand the characteristics of and treatment
strategy for esophageal NETs.
Methods: We collected data on esophageal NET patients from 25 hospitals in Korea from 2002–2012. The incidence,
location, clinical symptoms, histopathology, treatment response, and the biochemical, radiologic and endoscopic
characteristics of esophageal NETs were surveyed.
Results: Among 2,037 NETs arising in different gastrointestinal sites, esophageal NETs were found in 26 cases (1.3%).
The mean patient age was 60.12 ± 9.30 years with a 4:1 male predominance. In endoscopic findings, 76.9% (20/26) of
NETs were located in the lower third of the esophagus and the mean size was 2.34 ± 1.63 cm. At diagnosis, more than
half the patients (15/26, 57.7%) had regional lymph node metastasis or widespread metastasis. Endoscopic resection
was conducted in three cases, and in all three of them, lymph node metastasis was not found and tumor size was
below 1.0 cm. All tumors were completely removable through endoscopic procedures and there was no recurrence
during the follow-up period. Eighteen other patients received an operation, chemotherapy or both. Among them, nine
patients (50.0%) expired because of the progression of their cancer or post-operative complications. In Kaplan-Meier
survival analysis, only tumor size (more than 2.0 cm) showed prognostic significance (P = 0.045).
Conclusions: Despite the general assumption that gastrointestinal NETs are benign and slow-growing tumors, the
prognosis of advanced esophageal NETs is not favorable.
Keywords: Esophagus, Neuroendocrine tumor, Treatment, PrognosisBackground
Gastrointestinal (GI) neuroendocrine tumors (NETs) are
relatively rare, but their incidence has been sharply
rising in recent decades, and there have recently been
several studies on GI NETs [1-3]. According to the
organ distribution and frequency, pathogenesis and
treatment modality can differ in terms of prognosis;
therefore, it is important to understand the characteristics
of each organ through observation [1,4]. However, NETs
in the esophagus are exceedingly rare, and there have* Correspondence: limyj@dongguk.ac.kr
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unless otherwise stated.been no concrete data published on clinical features or
prognosis [5-7].
Few cases concerning primary esophageal NETs have
been reported in the literature. This is because the
neuroendocrine system is not well developed in the
esophagus [5]. Previously, one study reported on 8,305
NETs at different anatomical sites; however, only three
(0.04%) were reported to be esophageal NETs [8]. In
the latest multicenter research conducted in Korea in
2012, 4,951 cases of gastroenteropancreatic NETs were
analyzed, and of these, only 1.4% were reported to be
esophageal NETs [1].
Because of the paucity of data, the incidence, clinical
features of and treatment strategies for esophageal NETs. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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describing a definitive treatment strategy or prognosis
associated with primary esophageal NETs. Thus, this
multicenter study was undertaken to assess the incidence,
clinical characteristics, treatment modality and prognosis
of esophageal NETs. Here, we describe the incidence,
clinicopathologic features, immunohistochemical findings,
treatment modality and prognosis of 26 cases of primary
esophageal NETs that were treated at various centers over
a 10-year period (2002–2012).
Methods
Data collection
We collected and reviewed cases of patients diagnosed
with primary esophageal NETs from 2002–2012 at 25
universities and general hospitals in Korea. Inclusion
criteria were all pathologically confirmed NETs of the
esophagus, regardless of the quality of the pathologic
reports or histologic classification. Exclusion criteria
included the followings: (1) clinical data were not avail-
able even if the pathologic report proved it was an
esophageal NET; and (2) the patient had a history of
neuroendocrine carcinoma elsewhere. Patient age, gen-
der, presenting symptoms, methods of tumor diagnosis,
tumor size, multiplicity, mitotic count (about 10 high
power fields), Ki-67 labeling index, immunohistoche-
mical expression of synaptophysin and chromogranin,
lymphovascular invasion, perineural invasion, lymph node
metastasis, radiologic findings, types of treatment and
response to treatment were all surveyed.
The location of the tumor in the esophagus was deter-
mined on the basis of endoscopic findings and was divided
into three segments: an upper (15–24 cm from the incisor
teeth), a middle (24–32 cm from the incisor teeth) and a
lower (32–40 cm from the incisor teeth) one.
Cases had been clinically evaluated via endoscopic
ultrasonography (EUS), computed tomography (CT)
and positron emission tomography (PET). Regional LN
metastasis or distant metastasis was mainly evaluated
using imaging modalities including CT, EUS as well as
other modalities. If metastasis was uncertain, a biopsy
was performed at the suspected site. If an operation
had been performed, metastasis was confirmed by a
post-operative pathologic report. Neuroendocrine dif-
ferentiation was confirmed using immunohistochemical
staining for synaptophysin and chromogranin. Retro-
spective collection of gastroenteropancreatic NETs had
been approved by each Institutional Review Board of all
participating centers (“Busan National University” Hospital,
“Catholic University of Korea Seoul Saint” Hospital,
“Chonnam National University” Hospital, “Chungnam
National University” Hospital, Daegu Catholic University
Medical Center, “Dong-A University” Hospital, “Dongguk
University Ilsan” Hospital, “Eulji General” Hospital,Gachon University Gil Medical Center, “Gangwon
National University” Hospital, “Gyeongsang National
University” Hospital, Hanyang University Medical Center,
“Inha University” Hospital, “Inje University Haeundae
Paik” Hospital, “Inje University Sanggye Paik” Hospital,
Konkuk University Medical Center, Korea University
Medical Center, “Kosin University Gospel” Hospital,
National Cancer Center, “Seoul National University
Bundang” Hospital, “Seoul National University” Hospital,
“Soonchunhyang University” Hospital, Yeungnam University
Medical Center, “Yonsei University Kangnam Severance”
Hospital, “Yonsei University Sinchon Severance” Hospital).
Staging and classification
If data on tumor size and extension were available, we also
classified tumors according to the 2000 WHO classification
criteria into; well-differentiated endocrine tumors (WDETs),
well-differentiated endocrine carcinomas (WDECs), poorly
differentiated endocrine carcinomas/small cell carcinomas
(PDECs), mixed exocrine-endocrine carcinomas (MEECs),
and metastatic endocrine carcinomas (MECs) [9]. In
addition, the 2010 WHO classification was performed
based on the grading of the mitotic or Ki-67 labeling
index [9]. Mitosis was recorded as G1 (<2/10 HPF), G2
(2–20/10 HPF) or G3 (>20/10 HPF). The Ki-67-labeling
index was recorded as G1 (≤2%), G2 (3–20%) or G3
(>20%). Results of immunohistochemical staining, lym-
phovascular invasion, perineural invasion and lymph node
metastasis were presented as either positive or negative.
Survival outcome
Survival outcome data were derived through clinical
chart review. Overall survival was calculated from the
day of esophagogastroduodenoscopy and biopsy to the
date of death or last follow-up (months).
Statistical analysis
Statistical analysis was performed using SPSS software
(SPSS Corp, Chicago, IL, USA). Data were represented as
the mean ± standard deviation for continuous variables
or number (%) for categorical data. To estimate the associ-
ation between eligible variables and mean survival time,
Kaplan-Meier analysis was applied. A P-value less than
0.05 was considered statistically significant.
Results
Clinical characteristics
We collected 2,037 pathology reports of patients with
gastroenteropancreatic NETs. Among them, 26 cases
(1.3%) were detected in the esophagus. The clinical
characteristics of the 26 primary esophageal NETs are
summarized in Table 1. Mean patient age was 60.12 ±
9.30 (range, 45–76 years) with approximately a 4:1 male
predominance.
Table 1 Demographic and clinical characteristics of 26
esophageal neuroendocrine tumors
Number (%)
Male sex (%) 21 (80.8)




Abdominal discomfort 5 (19.2)
Weight loss 3 (11.5)
Melena 2 (7.7)
Hot flushes 1 (3.8)
Diarrhea 1 (3.8)
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found incidentally during a routine check-up esophagogas-
troduodenoscopy. The most common presenting symptom
was dysphagia (seven patients, 26.9%), and other symptoms
at diagnosis included abdominal discomfort (five patients,
19.2%), weight loss (three patients, 11.5%), and melena
(two patients, 7.7%). The typical carcinoid symptom
was documented in only one patient (3.8%). Most of
the patients (21/26, 80.8%) had an ECOG performance
status of 0 or 1.
Endoscopic findings
The endoscopic findings of the 26 cases of primary
esophageal NETs are summarized in Table 2. The primary
tumor was most frequently located in the lower esophagusTable 2 Endoscopic findings of 26 esophageal
neuroendocrine tumors
Endoscopic characteristics Total (%)
Tumor location
Upper (15–24 cm) 2 (7.7)
Middle (24–32 cm) 4 (15.4)
Lower (32–40 cm) 20 (76.2)
Tumor lesions
Single lesion 24 (92.3)
Multiple lesion 2 (7.7)
Tumor size (cm)






Elevated and depressed 6 (23.1)
Ulcerative 3 (11.5)(20 patients, 76.2%), followed by the middle esophagus
(four patients, 15.4%) and upper esophagus (two patients,
7.7%). The tumor was mainly represented in a single
lesion (24/26, 92.3%), and only two cases (7.7%) were
found to have multiple lesions. The sizes of the tumors
ranged from 0.5–7.5 cm (mean 2.34 ± 1.63 cm; median
1.9 cm). These tumors mostly represented elevated
polypoid or nodular elevated types (17/26, 65.4%). The
overlying surface showed mostly smooth, glistening and
tan-brown discoloration. Some other tumors were rep-
resented within the esophageal wall as large infiltrative
lesions of elevated and depressed types (6/26, 23.1%) or
ulcerated types (3/26, 11.5%).
Distribution of NETs according to the 2000 and 2010
WHO classification
The distribution of tumors according to their diagnosis
is shown in Table 3. In the classification of tumors
according to the 2000 WHO classification, three (11.5%)
were well-differentiated endocrine tumors, two (7.7%) were
mixed exocrine-endocrine carcinomas and 10 (38.5%) were
poorly differentiated endocrine carcinomas. The other
11 patients had no clinical records available, thus the
2000 WHO classification could not be applied. All re-
ported seven esophageal NETs based upon the 2010
WHO classification were categorized as neuroendocrine
carcinomas (G3).
At diagnosis, more than half the patients (15/26, 57.7%)
were found to have regional lymph node metastasis or
widespread metastasis. Among them, five patients had
lymphovascular metastasis and only one patient had a
perineural invasion.Table 3 Pathologic findings of 26 esophageal
neuroendocrine tumors
Clinical characteristics Number (%)
No. of patients 26 (100)
Tumor differentiation (2000 WHO classification)
Well differentiated 3 (11.5)
Mixed 2 (7.7)
Poorly differentiated 10 (38.5)
Not mentioned 11 (42.3)
Tumor differentiation (2010 WHO classification)
G1 (mitotic count <2, Ki-67 < 2) None
G2 (mitotic count 2–20, Ki-67 3–20) None
G3 (mitotic count >20, Ki-67 > 20) 7 (26.9)
Not mentioned 19 (73.0)
Tissue immunostaining
Synaptophysin 23 (88.5)
Chromogranin A 21 (80.8)
CD 56 8 (30.8)
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With regard to tissue immunostaining, 23 out of 26
patients (88.5%) were positive for synaptophysin, and 21
out of 26 patients (80.8%) were positive for chromogranin.
However, neither synaptophysin nor chromogranin were
detected in any of the serum samples. Urinary 5-
hydroxyindoleacetic acid (5-HIAA) levels were also
checked, and they were all negative.
Seventeen patients (65.4%) received their final diagnosis
through only endoscopic biopsy, while three patients got
their final diagnosis only after endoscopic removal of the
tumor. Six other patients received their final diagnosis
after the operation. There were two cases of esophageal
NETs with concurrent squamous cell carcinomas, and
one case of an esophageal NET accompanied by an
adenocarcinoma.Treatment modality
Disease metastasis was assessed using anatomical imaging
including CT (15/26, 57.7%), EUS (7/26, 26.9%), ultra-
sonography of the abdomen (2/26, 7.7%) and PET scans
(7/26, 26.9%).
Different treatment modalities and treatment responses
are described in Figure 1. Three patients received endo-
scopic resection only. Their tumor sizes were less than
1.0 cm and were of the elevated type in endoscopic
findings. There was no incidence of regional lymph
node metastasis, lymphovascular invasion or perineural
invasion. All three patients were diagnosed with carcin-
oid tumor and were alive without tumor recurrence
during the follow-up period.
Three patients received surgical resection only. Their
tumor sizes were more than 1.0 cm without regional
lymph node metastasis, lymphovascular invasion orFigure 1 Treatment modality (A) and treatment response (B) of 26 esop
NETs were already showing metastasis at the time of diagnosis, prognosis of
showed complete response and all of them were completely removable via eperineural invasion. In the 2000 WHO classification, all
three patients were categorized with poorly differentiated
carcinomas. These patients underwent radical resection
and esophageal-stomach anastomosis in the thorax or
neck. Among them, two cases were alive without recur-
rence during the follow-up period. However, in one
case, a 76-year-old man expired because of post-operative
pneumonia.
Three patients received combined modality treatment
including surgical resection and chemotherapy. In the
2000 WHO classification, one patient was categorized
with a poorly differentiated carcinoma, and two patients
were categorized with mixed endocrine-exocrine carcin-
omas. They received adjuvant systemic chemotherapy,
and one patient received additional local radiation therapy.
Among them, two patients were alive with progression of
the disease, and one patient was alive with stable disease.
Twelve patients were treated with only palliative chemo-
therapy. Each patient received different chemotherapy,
but most of the regimens began with cisplatin and etopo-
side (9/12, 75%) as the first combination therapy. When
the treatment was found not to be effective, secondary
combination therapy was tried, such as a cisplatin and
irinotecan regimen. During the follow-up period, eight
patients (7/12, 66.7%) had developed multiple liver, brain,
lung and bone metastases and died within 24 months.
Figure 2 shows treatment strategies that have been
organized from these collective cases to extract potential
valuable information.Patient survival
With respect to the final survival rate, 15 out of 26
patients were still alive, and nine patients had died.
Two remaining patients were either transferred to otherhageal neuroendocrine tumors (NETs). Because of most esophageal
them did not show benign course. On the other hand, 26.9% of patients
ndoscopic or surgical methods.
Figure 2 Treatment algorithm for patients with esophageal neuroendocrine tumors. It provide treatment strategies that have been organized
from these 26 collective cases.
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condition was not recorded. The median survival time
was 27.04 ± t17.16 months (1–59 months). According to
Kaplan-Meier survival analysis, only tumor size (more
than 2.0 cm) showed prognostic significance (P = 0.045)
(Figure 3). Other factors, including tumor location
(P = 0.345), regional lymph node metastasis (P = 0.597),
lymphovascular invasion (P = 0.096), synaptophysin expres-
sion (P = 0.155) and chromogranin expression (P = 0.557),
were not significantly associated with survival rate.Figure 3 Kaplan-Meier survival curve for patients with esophageal ne
less than 2.0 cm in size appeared to have significantly better survival compDiscussion
To our knowledge, this study, in which we have pre-
sented 26 cases of esophageal NETs, is to date the
largest study of its kind with long-term follow-up.
According to our data, the incidence of esophageal NETs
was 1.3% (26/2,037). The data in Korea show slightly
higher rates compared with Western countries [8]. This
may be due to genetic and racial differences, but can
also be correlated with the development and widespread
use of screening endoscopy [1].uroendocrine tumors based on tumor size. Patients with tumors
ared with those that had tumors greater than 2.0 cm in size.
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and we also found that males were predominant in our
study (male to female ratio of 4:1) [10]. In our study, all of
them occurred sporadically; that is, they were not found
to be of a familial type, such as type 1 multiple endocrine
neoplasia (MEN 1) or neurofibromatosis type 1 [11]. Dys-
phagia was the most common presenting symptom and
only one patient had a typical carcinoid symptom.
From endoscopic findings, esophageal NETs were typ-
ically a single lesion and commonly developed in the
lower third of the esophagus. This is because neuroen-
docrine cells are mainly distributed in mucosal glands of
the distal esophagus [6,12,13]. In 1990, Attar et al. noted
a predominant distribution of neuroendocrine carcinomas
in the lower third of the esophagus, similar to our results,
and related this to the abundance of endocrine cells in this
region [12,13].
Like other malignant tumors, prognosis of esophageal
NETs is influenced by the degree of lymph node metasta-
sis [2,13,14]. In this study, regional lymph node metastasis
or widespread metastasis of primary esophageal NETs was
57.7% (15 out of 26 cases) at diagnosis. This finding
underscored that a very high percentage of esophageal
NETs were already metastatic at the time of diagnosis,
compared with NETs that occurred at other anatomical
locations [15,16].
There are no data on prognostic factors associated
with esophageal NETs. Kaplan-Meier survival analysis
done in this study showed that size was an important
prognostic factor. A tumor size of more than 2.0 cm
appeared to be a prognostic factor for poor survival and
widespread metastasis of esophageal NETs. However,
all other parameters, as well as regional lymph node
metastasis and lymphovascular invasion, did not have
prognostic significance in this study. The lack of regional
lymph node metastasis and lymphovascular invasion
appeared to predict better survival, but it was not statisti-
cally significant. This was because chemotherapy affected
patient survival, which improved during the study period
[17-20].
In previous studies, inconsistent results were presented
on whether synaptophysin or chromogranin expression
was associated with better prognosis. One Korean multi-
center study reported that synaptophysin and chromogra-
nin expression were not significant prognostic factors
[1]. However, only in appendix NETs was synaptophysin
associated with a better prognosis [1]. In this study, we
performed survival analysis for esophageal NETs, but
synaptophysin and chromogranin were not prognostic
factors.
In addition, proliferative activity, assessed by mitotic
count or Ki-67 immunostaining, was previously described
as a significant prognostic factor in a previous study [21].
However, the mitotic index was recorded in only 20% ofcollected pathology reports and the Ki-67 labeling index
in only 10% of collected pathology reports because most
pathologic reports were made prior to the 2010 WHO
classification. Thus, we did not perform survival analysis
and multivariate analysis associated with the mitotic or
Ki-67 index.
Treatment of primary NETs depends on clinical staging
[2,22]. However, currently, a specific treatment algorithm
for esophageal NETs has not been established. Three of
the patients were treated using endoscopic resection with
a clear margin and there were no recurrences. Endoscopic
treatment was performed only on patients with tumors
less than 1.0 cm (range, 0.2–0.8 cm) and they did not have
regional lymph node metastasis. Six patients were treated
by surgical resection only, or combined chemotherapy.
Tumor size was more than 1.0 cm (range 1.4–1.7 cm)
in all six cases, and only one patient died because of a
post-operative complication. Twelve patients with re-
gional and distant metastasis were treated with only
palliative chemotherapy. The most frequent combin-
ation used was a cisplatin and etoposide regimen. This
combination may have resulted in most of the tumor
progression seen in up to two-thirds of patients. During
the follow-up period, eight patients developed widespread
metastases and died within 24 months after the diagnosis.
Therefore, there was a very limited role for chemotherapy
in the treatment of advanced esophageal NETs, which did
not show a benign clinical course [13,23,24]. In Figure 2,
algorithms are shown for the management of esophageal
NETs. Esophageal NETs, estimated endoscopically to be
<1.0 cm in diameter without lymph node metastasis, were
rarely metastatic. Therefore, these tumors were consid-
ered good candidates for endoscopic resection. However,
most of the esophageal NETs were already showing lymph
node or widespread metastasis at the time of diagnosis,
and were associated with a poor prognosis in spite of
systemic chemotherapy.
In addition, about half of the patients had poorly dif-
ferentiated neuroendocrine tumors (PEDCs) or small cell
carcinomas with respect to the 2000 WHO classification.
This was in regard to tumors of more than 1.0 cm in
diameter, commonly of the ulcerative type, and there was
early involvement of the esophageal wall, or it spread to
regional lymph nodes in the initial invasion of adjacent
organs. In our data on esophageal NETs, the 1-year sur-
vival rates of well-differentiated endocrine tumors was
100%, in contrast to 85% for well-differentiated endocrine
carcinomas and 33% for poorly differentiated endocrine
carcinomas.
The limitations of this study were as follows: First, dif-
ferent pathologists at each institution diagnosed esopha-
geal NETs. Because the international consensus has not
been achieved for histologic classification of esophageal
NETs, some pathologists did not mention their histology
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mainly used in this study. This is because most of the
pathologic reports were made before the 2010 WHO
classification. However, to our knowledge, this study
regarding the 26 cases of esophageal NETs was the largest
with a long-term follow-up period that was sufficient to
provide valuable clinical information.
Conclusions
Although the general incidence of gastrointestinal NETs
is sharply increasing, the incidence of esophageal NETs
is still very rare. Unlike other NETs that progress with a
benign course, most of the esophageal NETs were
already showing metastasis at the time of diagnosis, were
rapidly proceeding, and were associated with a poor
prognosis. However, when there was no lymphatic
metastasis, the size of the tumor was less than 1.0 cm, and
the NETs were not pathologically poorly differentiated,
the tumor was completely removable via an endoscopic
method and there was no recurrence during the follow-up
period.
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